International Edition
Latest News
Health

Expert Panel Finds Limited Consensus on Ketamine and Esketamine Clinical Practices

An international panel of experts has failed to reach a broad consensus on clinical protocols for ketamine and esketamine, exposing significant gaps in psychiatric practice. Published November 2 in The Journal of Clinical Psychiatry, the Delphi survey of…

Expert Panel Finds Limited Consensus on Ketamine and Esketamine Clinical Practices

An international panel of experts has failed to reach a broad consensus on clinical protocols for ketamine and esketamine, exposing significant gaps in psychiatric practice.

Published November 2 in The Journal of Clinical Psychiatry, the Delphi survey of 105 statements yielded agreement on only about one-third of the items evaluated.

The 21-member task force, representing researchers from six countries, struggled to align on fundamental treatment standards. For Dr. Gerard Sanacora, lead author and director of the Depression Research Program at Yale University, the result was expected.

“I was not completely surprised by the extent of disagreement,” Dr. Gerard Sanacora told Medscape Medical News.

Sanacora said that identifying these areas of nonconsensus is a vital finding that highlights where further evidence is needed to guide clinical decision-making.

Despite the broader discord, the panel found common ground on core safety protocols. The group endorsed both drugs as viable options for treatment-resistant depression, whether administered as monotherapy or alongside other treatments.

The experts collectively opposed the initiation of treatment in home settings, even when remote monitoring is available. They also flagged concerns regarding compounded oral ketamine lozenges, citing toxicity risks and a lack of safety data, while advising practitioners to generally avoid high-dose benzodiazepines.

“Ketamine treatments should be initiated in a healthcare facility with adequate infrastructure and resources, under the direct supervision of a healthcare provider,” Sanacora said.

Disagreements persisted on the comparative efficacy of IV ketamine versus intranasal esketamine. While the panel narrowly reached a consensus that intranasal esketamine is not superior to the IV formulation, they could not confirm if IV ketamine is more effective or if the two treatments provide comparable long-term results.

The task force also failed to meet the 75% agreement threshold on the use of these medications for conditions outside of major depression, such as obsessive-compulsive disorder, posttraumatic stress disorder, or borderline personality disorder. Further division remains on whether ketamine-assisted psychotherapy offers additive antidepressant benefits or if routine ECGs and laboratory testing should be mandatory for all patients.

The authors attributed the lack of consensus to a deficiency in high-quality evidence. To address these uncertainties, the task force identified an urgent need for head-to-head randomized trials and rigorous investigation into alternative formulations, including intramuscular ketamine.

Sanacora suggested that establishing a voluntary patient registry could generate the real-world data necessary to refine future clinical practices. Until such research emerges, the panel’s findings serve as an expert-driven reference, leaving individual practitioners to tailor assessments based on specific patient risk factors.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”